

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI47471

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
SEQUENCE:	3
CONVEYING PARTY DATA	
Name	Execution Date
Alkermes plc	11/14/2023
RECEIVING PARTY DATA	
Company Name:	Mural Oncology, Inc.
Street Address:	852 Winter Street
City:	Woburn
State/Country:	MAINE
Postal Code:	02451
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	62916936
Application Number:	17072725
Application Number:	17568281
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(612)335-5070
Email:	apsi@fr.com
Correspondent Name:	Tiffany Reiter
Address Line 1:	P.O. Box 1022
Address Line 4:	Minneapolis, MINNESOTA 55402
ATTORNEY DOCKET NUMBER:	57641-0005001
NAME OF SUBMITTER:	Rita Liston
SIGNATURE:	Rita Liston
DATE SIGNED:	02/23/2024
Total Attachments: 11	
source=57641 assignment from ALKS plc to Mural Inc#page1.tif	
source=57641 assignment from ALKS plc to Mural Inc#page2.tif	
source=57641 assignment from ALKS plc to Mural Inc#page3.tif	

source=57641 assignment from ALKS plc to Mural Inc#page4.tif
source=57641 assignment from ALKS plc to Mural Inc#page5.tif
source=57641 assignment from ALKS plc to Mural Inc#page6.tif
source=57641 assignment from ALKS plc to Mural Inc#page7.tif
source=57641 assignment from ALKS plc to Mural Inc#page8.tif
source=57641 assignment from ALKS plc to Mural Inc#page9.tif
source=57641 assignment from ALKS plc to Mural Inc#page10.tif
source=57641 assignment from ALKS plc to Mural Inc#page11.tif

DEED OF ASSIGNMENT (Patents)

This Deed of Assignment ("**Patent Assignment**"), effective as of 14 November, 2023, ("**Effective Date**"), is by and between Alkermes plc, a public limited company organized under the laws of Ireland, with registered number 498284 and whose registered address is Connaught House, 1 Burlington Road, Dublin 4, Ireland ("**Assignor**"), and Mural Oncology, Inc. a Delaware corporation, with a principal business address located at 852 Winter Street, Waltham, Massachusetts 02451, USA ("**Assignee**"). Assignor and Assignee are sometimes referred to herein individually as a "**Party**" and collectively as the "**Parties.**"

WHEREAS, Assignor is the owner of the patents and patent applications set forth in Schedule A (collectively, "**Assigned Patents**");

WHEREAS, Assignor has agreed to sell, convey, assign, transfer and deliver to Assignee all of Assignor's rights, title and interest in and to the Assigned Patents Assignee has agreed to purchase same from Assignor.

NOW, THEREFORE, in consideration of the foregoing and the mutual representations, warranties, covenants and agreements contained herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:

1. **Conveyance and Acceptance of Assigned Patents.** Assignor hereby sells, conveys, assigns, transfers and delivers to Assignee (and to Assignee's successors and permitted assigns), all of its right, title and interest in and to the Assigned Patents, including the right to claim priority to the Assigned Patents under the Paris Convention or any other national or international law, together with all proceeds, benefits, privileges, causes of action, and remedies relating to or arising from the Assigned Patents, all rights to bring oppose, defend and appeal (and/or to obtain relief in respect of) any proceedings, actions or claims, whether at law or in equity, for infringement or other violation of, or any other cause of action arising from ownership of, any of the Assigned Patents (past or present) against any third party, all rights to recover (and retain) damages, and profits and other remedies in respect of any past or future infringement or other

violation of the Assigned Patents; and Assignee hereby accepts such sale, conveyance, assignment, transfer and delivery.

2. **Further Assurances.** Assignor agrees, at Assignee's expense, to take such further action and to execute and deliver, or cause to be executed and delivered, such further instruments and take such other actions as may be necessary or desirable to carry out the transactions contemplated by this Patent Assignment, including signing all papers and documents, taking all lawful oaths and doing all acts necessary or required to be done to vest, perfect or confirm of record or otherwise in Assignee any and all right, title and interest in, to and under any of the Assigned Patents.

3. **Counterparts.** This Patent Assignment may be executed in multiple counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement. Transmission of an executed counterpart of this Patent Assignment (but for the avoidance of doubt not just a signature page) by email (in PDF, JPEG, digital image or other agreed format) shall take effect as delivery of an executed counterpart of this Assignment.4.

Governing law and jurisdiction. The validity, construction, and performance of this Assignment shall be governed by the laws of Ireland and shall be subject to the exclusive jurisdiction of the courts of Ireland to which the Parties submit.


[Signature Page Follows]

EXECUTED by the Parties as a deed and delivered on the Effective Date written at the start of this Deed of Assignment

ASSIGNOR:

GIVEN under the **COMMON SEAL** of
ALKERMES plc and delivered as a **DEED**

(Common Seal)




Director/Company Secretary



ASSIGNEE:

SIGNED and **DELIVERED** as a **DEED** by
MURAL ONCOLOGY, Inc.



~~Director~~/Company Secretary

[Signature Page to Patent Assignment]

Schedule A - Patents

Family Ref.	Title	Country	Sub Case	Case Type	Application Status	Application No.	Filing Date	Publication No.	Patent No.	Issue Date	Expiration Date
<i>Nonviral/in-vitro Families</i>											
ALW-027	IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	US		PRO	Expired	63022 853	11-May-2020				
		US		ORD	Pending	17315,973	10-May-2021	US 2021-0371486			
		WO		ORD	Pending	PCT/US21/131611	10-May-2021	WO 2021-231316			
		AU		PCT	Pending	2021270745	10-May-2021	AU 2021270745			
		BR		PCT	Pending	BR 112022022764	10-May-2021	BR 112022022764			
		CA		PCT	Pending	3172871	10-May-2021	CA 3,172,871			
		CN		PCT	Pending	202180042991.8	10-May-2021	CN 115916242			
		EA		PCT	Pending	202293288	10-May-2021	EA 202293288			
		EP		PCT	Pending	21804863.5	10-May-2021	EP 4 149 515			
		HK		REP	Pending	62023072893.2	10-May-2023	HK 40083713			
		IL		PCT	Pending	298065	10-May-2021	IL 298065			
		IN		PCT	Pending	202247068471	10-May-2021	IN 202247068471A			
		JP		PCT	Pending	2023525565	10-May-2021	JP 2023525565			
		KR		PCT	Pending	20230009446	10-May-2021	KR 20230009446			
		MX		PCT	Pending	MX/A/2022014164	10-May-2021	MX/A/2022014164			
		NZ		PCT	Pending	794237	10-May-2021				
		SG		PCT	Pending	11202254810V	11-May-2021				
		TW		ORD	Pending	110116903	11-May-2021	TW 202207970			
		ZA		PCT	Pending	202212194	10-May-2021				
<i>ALW-028 METHODS OF PURIFICATION</i>											
		US		PRO	Expired	62965,578	24-Jan-2020				
		US		ORD	Pending	171154,108	21-Jan-2021	US 2021-0253631			
		WO		ORD	Pending	PCT/US21/14306	21-Jan-2021	WO 2021-150674			
		AU		PCT	Pending	2021210905	21-Jan-2021	AU 2021210905			
		BR		PCT	Pending	BR112022014567.5	21-Jan-2021	BR 112022014567			
		CA		PCT	Pending	3,165,442	21-Jan-2021	CA 3,165,442			
		CN		PCT	Pending	CN 202180023220.4	21-Jan-2021	CN 115333394			
		EA		PCT	Pending	202292184	21-Jan-2021	EA 202292184			
		EP		PCT	Pending	21744559.2	21-Jan-2021	EP 4 093 755			
		HK		REP	Pending	HK 62022066219.6	21-Jan-2021	40076482A			
		IL		PCT	Pending	294901	21-Jan-2021	IL 294901			
		IN		PCT	Pending	202217047714	21-Jan-2021				
		JP		PCT	Pending	2022-544797	21-Jan-2021	JP 2023511946			
		KR		PCT	Pending	10-2022-7029145	21-Jan-2021	KR 20220143676			
		MX		PCT	Pending	MX/a/2022009134	21-Jan-2021				
		NZ		PCT	Pending	791005	21-Jan-2021				
		SG		PCT	Pending	11202251364J	21-Jan-2021				
		TW		ORD	Pending	110102511	22-Jan-2021	TW 202140512			
		ZA		PCT	Pending	202208113	21-Jan-2021				

ALW-032	IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME	US	PRO	Expired	63/022,860	11-May-2020	US 2021-0395325	
		US	ORD	Pending	17/315,974	10-May-2021	WO 2021-231319	
		WO	ORD	Pending	PCT/US21/31616	10-May-2021	AU 2021-269585	
		AU	PCT	Pending	2021269585	10-May-2021	BR 112022022869	
		BR	PCT	Pending	112022022869-4	10-May-2021	CA 3,172,874	
		CA	PCT	Pending	3,172,874	10-May-2021	CN 115987307	
		CN	PCT	Pending	202180040284.5	01-May-2021	EP 4,149,514	
		EA	PCT	Pending	202293269	10-May-2021	IL 298064	
		EP	PCT	Pending	21804274.5	10-May-2021	JP 2023526024	
		HK	REP	Pending	HK 62023079498.9	10-May-2021	KR 20230008759	
		IL	PCT	Pending	298064	10-May-2021		
		IN	PCT	Pending	202247058510	10-May-2021		
		JP	PCT	Pending	2022-568632	10-May-2021		
		KR	PCT	Pending	10-2022-7041366	10-May-2021		
		MX	PCT	Pending	MX/a/2022014163	01-May-2021		
		NZ	PCT	Pending	794232	10-May-2021		
		SG	PCT	Pending	12022584830X	11-May-2021		
		TW	ORD	Pending	110116904	11-May-2021	TW 202207971	
		ZA	PCT	Pending	202212125	10-May-2021		

ALW-3067	Ligands Modified by Circular Permutation as Agonists and Antagonists	US	PRO	Expired	61/657,378	08-Jun-2012		
		US	PRO	Expired	61/723,081	06-Nov-2012		
		US	PRO	Expired	61/657,264	08-Jun-2012		
		US	PRO	Expired	61/778,575	13-Mar-2013		
		US	PRO	Expired	61/657,285	08-Jun-2012		
		US	PRO	Expired	61/778,812	13-Mar-2013		
		US	2	Granted	13/911,827	06-Jun-2013	US 2013-0336924	06-Jun-2033
		US	3	Granted	14/182,536	18-Feb-2014	US 2014-0234962	06-Jun-2033
		US	4	Granted	15/218,193	25-Jun-2016	US 2017-0044228	06-Jun-2033
		US	5	Pending	16/519,231	23-Jul-2019	US 2020-0040053	
		WO	PCT	Pending	PCT/US13/44556	06-Jun-2013	WO 2013/184942	
		AL	EPP	Granted	13801437.8	06-Jan-2015	AL-P-2018-346	06-Jun-2033
		AL	D	Granted	18162555.9	19-Mar-2018	3401402	06-Jun-2033
		AT	EPP	Granted	13801437.8	06-Jan-2015	EP2859015	06-Jun-2033
		AT	D	Granted	18162555.9	19-Mar-2018	3401402	06-Jun-2033
		AU	PCT	Granted	2013271545	30-Sep-2014	2013271545	06-Jun-2033
		AU	D	Granted	2015268652	12-Oct-2015	2015268652	06-Jun-2033
		AU	D1	Granted	2018200597	24-Jan-2018	2018200597	06-Jun-2033
		BA	EPP	Granted	13801437.8	06-Jan-2015	EP2859015	06-Jun-2033
		BE	EPP	Granted	13801437.8	06-Jan-2015	EP2859015	06-Jun-2033
		BE	D	Granted	18162555.9	19-Mar-2018	3401402	06-Jun-2033
		BG	EPP	Granted	13801437.8	06-Jan-2015	EP2859015	06-Jun-2033
		BG	D	Granted	18162555.9	19-Mar-2018	3401402	06-Jun-2033
		CA	PCT	Granted	2,869,787	06-Oct-2014	2869787	06-Jun-2033

CH		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
CH	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
CY		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
CY	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
CZ		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
CZ	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
DE		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
DE	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
DK		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
DK	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
EE		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
EE	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
EP		PCT	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
EP	D	DIV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
EP	D2	DIV	Pending	20201402.3	06-Jun-2013	3401402	14-Oct-2020	06-Jun-2033
ES		EPP	Granted	13801437.8	06-Jan-2015	EP 3825405		
ES	D	EDV	Granted	18162555.9	19-Mar-2018	EP2859015	21-Mar-2018	06-Jun-2033
FI		EPP	Granted	13801437.8	06-Jan-2015	3401402	14-Oct-2020	06-Jun-2033
FI	D	EDV	Granted	18162555.9	19-Mar-2018	EP2859015	21-Mar-2018	06-Jun-2033
FR		EPP	Granted	13801437.8	06-Jan-2015	3401402	14-Oct-2020	06-Jun-2033
FR	D	EDV	Granted	18162555.9	19-Mar-2018	EP2859015	21-Mar-2018	06-Jun-2033
GB		EPP	Granted	13801437.8	06-Jan-2015	3401402	14-Oct-2020	06-Jun-2033
GB	D	EDV	Granted	18162555.9	19-Mar-2018	EP2859015	21-Mar-2018	06-Jun-2033
GR		EPP	Granted	13801437.8	06-Jan-2015	3401402	14-Oct-2020	06-Jun-2033
GR	D	EDV	Granted	18162555.9	19-Mar-2018	EP2859015	21-Mar-2018	06-Jun-2033
HK	(EP)	REP	Granted	15104304.6	06-May-2015	1203969	05-Jul-2019	06-Jun-2033
HK	D	REP	Granted	18162555.9	19-Mar-2018	1283216	14-May-2021	06-Jun-2033
HK	D2	DIV	Pending	42021042984.1	21-Nov-2021	HK 4005312		
HK	EPD	REP	Pending	19123172.9	06-Feb-2020	HK 40053172		
HR		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
HR	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
HU		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
HU	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
IE		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
IE	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
IS		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
IS	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
IT		EPP	Granted	13801437.8	06-Jan-2015	502018000017921	21-Mar-2018	06-Jun-2033
IT	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
JP		PCT	Granted	2015-516221	02-Dec-2014	6388408	24-Aug-2018	06-Jun-2033
JP	D	DIV	Granted	2017-151506	04-Aug-2017	6545759	28-Jun-2019	06-Jun-2033
JP	D1	DIV	Granted	2019-113671	19-Jun-2019	7048543	28-Mar-2022	06-Jun-2033
JP	D3	DIV	Pending	2021-195887	02-Dec-2021			
JP	D4	DIV	Pending	2023-085990	01-Jun-2023			
U		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033

LI	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
LT		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
LT	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
LU		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
LU	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
LV		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
LV	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
MC		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
MC	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
ME		EPP	Granted	13801437.8	06-Jan-2015	P-2018/155	21-Mar-2018	06-Jun-2033
MK		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
MK	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
MT		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
MT	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
NL		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
NL	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
NO		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
NO	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
NZ		PCT	Granted	630849	11-Sep-2014	630849	02-Aug-2016	06-Jun-2033
NZ	D	DIV	Granted	715099	11-Dec-2015	715099	22-Mar-2019	06-Jun-2033
PL		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
PL	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
PT		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
PT	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
RO		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
RO	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
RS		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
RS	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
SE		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
SE	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
SI		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
SI	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
SK		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
SK	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
SM		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
SM	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033
TR		EPP	Granted	13801437.8	06-Jan-2015	EP2859015	21-Mar-2018	06-Jun-2033
TR	D	EDV	Granted	18162555.9	19-Mar-2018	3401402	14-Oct-2020	06-Jun-2033

ALW-3078	COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY	US	PRO	Expired	62/860,182	11-Jun-2019	
		US	PRO	Expired	62/924,356	22-Oct-2019	
		US	PRO	Expired	62/932,160	07-Nov-2019	
		US	UTILITY	Pending	16/898,008	10-Jun-2020	US 2021-0038684
		WO	ORD	Pending	PCT/EP2020/066226	11-Jun-2020	WO/2020/249687
		AU	PCT	Pending	2020292590	11-Jun-2020	
		BR	PCT	Pending	BR 112021025035-2	11-Jun-2020	
		CA	PCT	Pending	3143097	11-Jun-2020	
		CN	PCT	Pending	20208005682.X	11-Jun-2020	CN 114423446A
		EA	PCT	Pending	202290010	11-Jun-2020	
		EP	PCT	Pending	20732575.4	11-Jun-2020	EP 3983530
		IL	PCT	Pending	288764	11-Jun-2020	
		IN	PCT	Pending	202217001391	11-Jun-2020	10/2022
		JP	PCT	Pending	2021-573568	11-Jun-2020	2022-535610
		KR	PCT	Pending	10-2022-7000553	11-Jun-2020	KR 20220044481
		MX	PCT	Pending	MX/A/2021/015353	11-Jun-2020	
		NZ	PCT	Pending	784107	11-Jun-2020	
		SG	PCT	Pending	11202113616Q	11-Jun-2020	
		ZA	PCT	Pending	2022000387	11-Jun-2020	
		HK	REP	Pending	62022052350.5	25-Apr-2022	
ALW-3079	Immunostimulatory Agents in Combination with Angiogenesis Inhibitors	US	PRO	Expired	63/010,185	15-Apr-2020	US 2021-0338656
		US	1	Pending	17/231,307	15-Apr-2021	WO 2021211860
		WO	ORD	Pending	PCT/AUS21/27507	15-Apr-2021	AU 2021254793
		AU	PCT	Pending	2021254793	15-Apr-2021	CA 3,275,356
		CA	PCT	Pending	3175356	15-Apr-2021	EP 4 135 752
		EP	PCT	Pending	21789134.0	15-Apr-2021	JP 2023522211
		JP	PCT	Pending	2022-563014	15-Apr-2021	CN 115916241
		NZ	PCT	Pending	793381	15-Apr-2021	BR 112022020846
		CN	PCT	Pending	202180040880.3	15-Apr-2021	IL 297280
		BR	PCT	Pending	112022020846-4	15-Apr-2021	KR 20230026994
		EA	PCT	Pending	202292927	15-Apr-2021	
		IL	PCT	Pending	297280	15-Apr-2021	
		KR	PCT	Pending	10-2022-7039824	15-Apr-2021	
		MX	PCT	Pending	MX/A/2022/012982	15-Apr-2021	
		IN	PCT	Pending	202247065177	15-Apr-2021	
		SG	PCT	Pending	11202254038B	15-Apr-2021	
		ZA	PCT	Pending	2022/11128	15-Apr-2021	
		HK	REP	Pending	62023071250.2	15-Apr-2021	

ALW-3081	COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY									
	US	PRO	Expired	62/860,182	11-Jun-2019	US 2021-0052694	11,246,906	15-Feb-2022	06-Aug-2040	
	US	PRO	Expired	62/932,160	07-Nov-2019	WO 2020/249683				
	US	PRO	Expired	62/924,356	22-Oct-2019					
	US	ORD	Granted	16/897,920	10-Jun-2020					
	WO	PRI	Pending	PCT/EP2020/066234	11-Jun-2020					
	AU	PCT	Pending	2020291109	11-Jun-2020					
	BR	PCT	Pending	112021024966-4	11-Jun-2020					
	CA	PCT	Pending	3,143,098	11-Jun-2020					
	CN	PCT	Pending	202080056860.0	11-Jun-2020	114555126A				
	EA	PCT	Pending	202290009	11-Jun-2020					
	EP	PCT	Pending	20732576.2	11-Jun-2020	3982998				
	IL	PCT	Pending	288756	11-Jun-2020					
	IN	PCT	Pending	202217001396	11-Jun-2020					
	JP	PCT	Pending	2021-573569	11-Jun-2020	202535972				
	KR	PCT	Pending	10-2022-7000547	11-Jun-2020	20220044480				
	MX	PCT	Pending	MX/A/2021/015354	11-Jun-2020					
	SG	PCT	Pending	11202113614X	11-Jun-2020					
	ZA	PCT	Pending	2022/00388	11-Jun-2020					
	HK	REP	Pending	62022052347.1	25-Apr-2022	40063637				
	US	CON	Pending	17/668,251	04-Jan-2022	2022/0241370A1				
	NZ	PCT	Pending	784063	11-Jun-2020					
ALW-3082	IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS									
	US	PRO	Expired	62/916,936	18-Oct-2019	US 2021-0163596	11,248,050	15-Feb-2022	16-Oct-2040	
	US	ORD	Granted	17/072,725	16-Oct-2020	US 2022-0227868				
	US	CON	Pending	17/668,281	04-Jan-2022	WO 2021/074689				
	WO	ORD	Pending	PCT/IB2020/000860	16-Oct-2020					
	AU	PCT	Pending	2020367403	28-Mar-2022					
	BR	PCT	Pending	112022007158-2	13-Apr-2022					
	CA	PCT	Pending	3,157,229	06-Apr-2022					
	CN	PCT	Pending	202080072726.X	15-Apr-2022	114555110A				
	EA	PCT	Pending	202291180	17-May-2022					
	EP	PCT	Pending	20817472.2	03-May-2022	4045077				
	IL	PCT	Pending	92219	13-Apr-2022					
	IN	PCT	Pending	202217028101	16-May-2022					
	JP	PCT	Pending	2022-523000	13-Apr-2022					
	KR	PCT	Pending	10-2022-7014302	27-Apr-2022					
	MX	PCT	Pending	MX/A/2022/004577	16-Oct-2020					
	NZ	PCT	Pending	786583	16-Oct-2020					
	SG	PCT	Pending	11202203045U	16-Oct-2022					
	ZA	PCT	Granted	2022/03567	14-Sep-2022		2022/03567	30-Nov-2022	16-Oct-2040	
	HK	REP	Pending	62022063740	16-Oct-2020	40075878A				

ALW-3085 IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS	US	PRO	Expired	63/010,185	15-Apr-2020	
	US	PRO	Expired	63/165,391	24-Mar-2021	
	US	ORD	Pending	17/231,309	15-Apr-2021	US 2021-0347837
	WO	ORD	Pending	PCT/US21/127503	15-Apr-2021	WO2021211857
	CA	PCT	Pending	2,869,674	06-Jun-2013	
	AU	PCT	Pending	2021257874	15-Apr-2021	
	EP	PCT	Pending	. 21788817.1	15-Apr-2021	
	JP	PCT	Pending	2022-562837	15-Apr-2021	
	NZ	PCT	Pending	793377	15-Apr-2021	
	CN	PCT	Pending	202180042246.3	15-Apr-2021	115697376A
	BR	PCT	Pending	BR 112022020871-5	15-Apr-2021	
	EA	PCT	Pending	202292926	15-Apr-2021	202292926
	IL	PCT	Pending	297279	15-Apr-2021	
	KR	PCT	Pending	10-2022-7039974	15-Apr-2021	
	MX	PCT	Pending	MX/A/2022/012983	15-Apr-2021	
	IN	PCT	Pending	202247065059	15-Apr-2021	
	SG	PCT	Pending	11202254043X	15-Apr-2021	
	ZA	PCT	Pending	2022/11126	15-Apr-2021	
	HK	REP	Pending	62023071251.0	15-Apr-2023	

ALW-3087 COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY	US	PRO	Expired	63/309,199	11-Feb-2022	
	WO	PRI	Pending	PCT/US23/62433	10-Feb-2023	WO 2023/154894

Family Ref.	Title	Country	Sub Case	Case Type	Application Status	Application No.	Filing Date	Publication No.	Patent No.	Issue Date	Expiration Date
Other Oncology Families											
ALW-3084	UPAR ANTIBODIES AND FUSION PROTEINS WITH THE SAME	US		PRO	Expired	63/166,313	24-Mar-2021				24-Mar-2022
		US		ORD	Pending	17/702,329	23-Mar-2022	US 2022-0340678			
		WO		ORD	Pending	PCT/2022/021522	23-Mar-2022	WO 2022-0204267			
		CA		PCT	Pending	3,210,385	23-Mar-2022				
		MX		PCT	Pending	MX/a/2023/011268	23-Mar-2022				
		IL		PCT	Pending	306074	24-Mar-2022				
		NZ		PCT	Pending	803069	25-Mar-2022				
		AU		PCT	Pending	2022241762	26-Mar-2022				
		SG		PCT	Pending	11202306409W	27-Mar-2022				
		BR		PCT	Pending	BR112023018768-0	28-Mar-2022				
		EP		PCT	Pending	22776558.3	29-Mar-2022				
		IN		PCT	To be filed						
		KR		PCT	To be filed						
		ZA		PCT	To be filed						
		CN		PCT	To be filed						
ALW-3086	INTERLEUKIN 18 VARIANTS	US	1	PRO	Pending	63/424,701	11-Nov-2022	n/a			11-Nov-2023
		US		ORD	Pending	18/496,582	27-Oct-2023				
		WO		ORD	Pending	PCT/US23/780830	27-Oct-2023				